Media coverage about Edwards Lifesciences (NYSE:EW) has been trending somewhat positive on Saturday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Edwards Lifesciences earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.5686048037353 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Edwards Lifesciences' (EW) THVT Likely to Drive Q1 Earnings (finance.yahoo.com)
- Edwards Lifesciences’ (EW) THVT Likely to Drive Q1 Earnings (zacks.com)
- Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 6,300 Shares of Stock (americanbankingnews.com)
- Bear of the Day: Barrick Gold (ABX) (finance.yahoo.com)
- Edwards Lifesciences (EW) Upgraded by Zacks Investment Research to Buy (americanbankingnews.com)
Shares of NYSE EW traded down $1.47 during midday trading on Friday, reaching $137.09. 1,540,202 shares of the stock were exchanged, compared to its average volume of 1,328,212. The company has a market cap of $29,100.88, a PE ratio of 36.08, a price-to-earnings-growth ratio of 2.03 and a beta of 0.58. Edwards Lifesciences has a 52-week low of $97.63 and a 52-week high of $143.22. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The business had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same period in the previous year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. analysts anticipate that Edwards Lifesciences will post 4.53 EPS for the current year.
Several research firms have weighed in on EW. Cowen restated a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences in a report on Thursday, February 1st. Stifel Nicolaus restated a “buy” rating and set a $155.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. JMP Securities raised their target price on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a report on Friday, February 2nd. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Finally, Guggenheim restated a “buy” rating and set a $162.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $145.92.
In related news, VP Larry L. Wood sold 6,300 shares of the business’s stock in a transaction that occurred on Monday, April 16th. The shares were sold at an average price of $138.97, for a total value of $875,511.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 5,633 shares of the business’s stock in a transaction that occurred on Wednesday, April 11th. The shares were sold at an average price of $139.42, for a total transaction of $785,352.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 197,236 shares of company stock valued at $26,488,281. 1.84% of the stock is owned by insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.